Recent bullish coverage from firms such as Canaccord Genuity, highlighting Twist Bioscience (TWST) silicon-based lab-on-a-chip platform and AI-enabled drug discovery efforts, has pushed Twist Bioscience stock firmly into focus for many investors.

That bullish research comes after a sharp move in the Twist Bioscience share price. The stock closed at US$82.87, with a 30 day share price return of 66.44% and a 1 year total shareholder return of 130.90%. This recent performance has pushed the company firmly into focus for investors.

If you are looking beyond Twist Bioscience for other companies linked to AI advances in healthcare and life sciences, this is a good moment to scan the market using our 40 healthcare AI stocks

With Twist Bioscience now trading near US$82.87 after a sharp rally and mixed signals on fair value estimates, investors are left with a key question: is there still a reasonable entry point here, or is the market already pricing in future growth?

Most Popular Narrative: 42.9% Overvalued

Against Twist Bioscience's last close at $82.87, the most widely followed narrative anchors on a fair value of $58.00, creating a wide valuation gap for investors to weigh.

Intensifying adoption of AI-driven drug discovery, coupled with swelling investment in next-gen biomanufacturing, is unleashing new high-value use cases for customized DNA and antibody libraries. This is making Twist the partner of choice for large pharma and synthetic bio innovators, driving not only higher ASPs but also recurring multi-year contracts that can structurally increase revenue and margin visibility.

Want to see what kind of growth and margin profile that statement is built on? The narrative leans on ambitious revenue compounding, rising profitability and a rich future earnings multiple that together support the $58.00 fair value anchor.

Result: Fair Value of $58.00 (OVERVALUED)

However, Twist Bioscience still faces meaningful risks, including continued operating losses and potential pricing pressure in synthetic DNA and NGS that could challenge the bullish narrative.

Another View: Twist Bioscience Through a Cash Flow Lens

While the most popular Twist Bioscience narrative points to a fair value of $58.00 and labels the stock as overvalued at $82.87, the SWS DCF model points in a different direction, with an estimated future cash flow value of $137.97, suggesting the shares are trading at a discount. When two methods pull in opposite directions like this, which one do you lean on more heavily in your own work?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Twist Bioscience for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Given the split views on Twist Bioscience, do you feel the momentum justifies the risks and rewards being debated, or not yet? If you want to move quickly and shape your own view, start by weighing both sides through the 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Twist Bioscience stock?

If Twist Bioscience has sharpened your interest, do not stop here. Broaden your watchlist with focused stock ideas surfaced by the Simply Wall St Screener.

• Target potential mispricing by scanning companies highlighted in our 48 high quality undervalued stocks so you are not leaving possible opportunities unexplored.
• Strengthen your defensive side by reviewing businesses featured in the 65 resilient stocks with low risk scores before market conditions shift again.
• Spot early-stage potential by checking companies in the 24 elite penny stocks with strong financials that already have financial metrics worth a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.